BIVI Profile
BioVie Inc., a clinical-stage biopharmaceutical company, specializes in the discovery, development, and commercialization of innovative drugs aimed at treating chronic and debilitating conditions. The Company's diverse pipeline is focused on addressing complex diseases with significant unmet medical needs. Key products under development include BIV201, which has completed Phase IIa clinical trials for treating ascites associated with chronic liver cirrhosis. This drug represents a significant advancement in the management of fluid retention and abdominal swelling caused by liver disease.
Another cornerstone of BioVie’s pipeline is NE3107, a potentially selective inhibitor targeting inflammatory extracellular signal-regulated kinase (ERK). NE3107 is currently in Phase III clinical trials for mild to moderate Alzheimer's disease, reflecting the Company’s commitment to tackling neurodegenerative conditions. Additionally, NE3107 is in Phase II trials for Parkinson’s disease and is in pre-clinical development for multiple myeloma and prostate cancer, showcasing its broad potential in oncology and neurodegenerative diseases.
Formerly known as NanoAntibiotics, Inc., BioVie rebranded in July 2016 to better reflect its focus on advanced biopharmaceuticals. Since its incorporation in 2013, the Company has leveraged its expertise in drug development to advance therapeutic solutions that address critical health challenges. BioVie’s innovative approach and strategic pipeline aim to transform the treatment landscape for chronic diseases and enhance patient outcomes.
Headquartered in Carson City, Nevada, BioVie Inc. continues to drive forward with its mission to develop and bring to market transformative therapies. The Company’s dedication to research and development, coupled with its robust clinical pipeline, positions it as a key player in the biopharmaceutical industry, committed to improving the quality of life for patients with complex medical conditions.
|
